Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Abstract

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• University of Gothenburg SE
• Harvard University US
• Thomayer University Hospital CZ
• National Cerebral and Cardiovascular Center JP
• Amsterdam UMC Location University of Amsterdam NL
• Iuliu Hațieganu University of Medicine and Pharmacy RO
• Deutsches Herzzentrum München DE
• Charité - Universitätsmedizin Berlin DE
• Universidade de São Paulo BR
• Baylor College of Medicine US
• Technical University of Munich DE
• Peoples' Friendship University of Russia RU
• University of Amsterdam NL
• University of Pavol Jozef Šafárik SK
• VieCuri Medisch Centrum NL
• Servicio Diabetología Hospital Córdoba AR
• University of East Anglia GB
• Tohoku University Hospital JP
• Novartis (Switzerland) CH
• Universidade Federal de São Paulo BR
• Sahlgrenska University Hospital SE
• McGill University CA
• Faculdade Evangélica do Paraná BR
• Moscow City Hospital No 29 RU
• Manipal Hospital IN
• Medisch Centrum Alkmaar NL
• German Centre for Cardiovascular Research DE
• University of Szeged HU

Related Publications